about
Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.Phase II study on lapatinib in advanced EGFR-positive chordoma.Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three VersSynovial sarcoma: retrospective analysis of 250 patients treated at a single institution.Periosteal osteosarcoma: a single-institution experience.Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.Emerging therapeutic targets for synovial sarcoma.Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberansGemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of boneAdjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions.Advanced chondrosarcomas: role of chemotherapy and survival.Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.Osteosarcoma follow-up: chest X-ray or computed tomography?The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future.Diagnosis and prognosis for the Ewing family of tumors.Analysis of risk factors for central venous catheter-related complications: a prospective observational study in pediatric patients with bone sarcomas.State-of-the-art approach for bone sarcomas.Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?Palliative embolisation for advanced bone sarcomas.High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma.Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.Imaging in bone sarcomas. The chemotherapist's point of view.Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years.MRgFUS new applications in musculoskeletal pathology: a miscellaneous case review.Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/- /Apc1638(N/+) mice.Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.Ewing sarcoma in patients over 40 years of age: a prospective analysis of 31 patients treated at a single institution.
P50
Q30249799-A55321CC-6695-4FA5-BC1D-71F181C0ADFAQ33274760-52D02514-A240-4F48-A3E2-74B356538AE7Q33275974-7728D438-1B60-405B-85A7-40FF82384AD7Q33382768-A71C8950-9B46-477A-A166-9DA7106BB83BQ33384413-A9B105BD-2497-4AB9-A9C5-5F33ED3E5918Q33390359-9A328DED-5CCB-42D5-9C31-C3D9328E64BFQ33410703-A3EAC082-DA7F-4B51-8FA3-2DD93806ED52Q33419286-DDBBE768-659A-4D78-A1AE-6308387D8E97Q33425709-D166E885-6D70-44C4-8374-250CB6286649Q34607877-52FC010A-B788-41ED-AA43-C7AB5175B016Q34628287-46C05DDF-BEFD-4277-B3DE-0F1A68B7F973Q34638074-9A4CF07C-6C3C-466F-A2AA-AE01DED1E386Q34660607-F19B4F85-5BDA-4026-9BF4-0338D1296BA0Q35061368-74115E26-6F48-4376-8F90-5EDF2909E48FQ35958157-C80B2BC1-356B-4F77-A3B8-08C057940550Q35995283-A0EF838A-A748-4FD2-942F-E4A9794CB4CCQ36838972-D2B38D82-1CEF-4632-976C-70FE0393346BQ36927145-7A2D357B-F9DA-4C90-A2A8-85ECF28C63ECQ37265042-89384D9C-EF2C-4C7D-AA58-B7432575463FQ37355439-13818C7B-44D4-4A02-AE64-C6F4E83F5ADDQ37560522-A181F481-9B41-4AFF-B41F-E34B4A047C77Q37640670-76BF41F1-7C25-4E8F-B45C-EAE6CEDF36AFQ37705060-46A88CC3-1502-4314-8378-AEFC383B79C0Q38088856-CC4C1FF3-CB87-430B-BB83-E7453EA4DAC0Q38115638-8424760F-C1E6-48F2-90EE-6091D02C2170Q38208930-527363FF-F29C-452B-BFDA-9F2B725B847EQ38889474-AE0A407A-49B6-48C8-BAA2-4632AF71CA8CQ39243816-DB5BF8B7-4E8F-426B-969F-8E4D6CF8E7FAQ40366561-6CEABCDC-E010-452B-B8D8-503AEFFFD524Q40448095-7EC38000-213C-4058-8F50-D5EDA4B5BF01Q41421308-27AFE935-A6D0-4029-BD06-E65F6B1E1F8BQ41737244-E347EB6B-5EAD-49E1-B59C-3A509D0B44F8Q45093063-8C95E517-4165-4E25-994D-7497D87BD2A2Q45405959-5489A830-5F83-41E7-A103-111B62C679C3Q45908849-2A02BE28-C8C9-4580-8FC8-B94DCC97A449Q45957450-47527DF3-43F1-4761-B25B-17CE40267763Q46568773-BFD9740B-6387-4A0E-A1F5-A010ADE24E43Q46787977-CD332E50-9DFD-491D-8EB5-C70067D69CDFQ48563215-BC3EABF0-9979-4FF1-A9B1-ECD79F7F4584Q50234728-762084CB-4DD1-4B29-9D29-954BA1016343
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Emanuela Palmerini
@ast
Emanuela Palmerini
@en
Emanuela Palmerini
@es
Emanuela Palmerini
@sl
type
label
Emanuela Palmerini
@ast
Emanuela Palmerini
@en
Emanuela Palmerini
@es
Emanuela Palmerini
@sl
prefLabel
Emanuela Palmerini
@ast
Emanuela Palmerini
@en
Emanuela Palmerini
@es
Emanuela Palmerini
@sl
P1053
Q-8562-2016
P106
P1153
16444890000
P21
P31
P3829
P496
0000-0003-3406-6705